950140 — Englewood Lab Income Statement
0.000.00%
Last trade - 00:00
- KR₩303bn
- KR₩297bn
- $158.41m
- 62
- 45
- 65
- 62
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | ARS | ARS | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 114 | 116 | 141 | 117 | 158 |
Cost of Revenue | |||||
Gross Profit | 22.2 | 21.3 | 30.1 | 20 | 36.6 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 109 | 110 | 126 | 110 | 136 |
Operating Profit | 5.79 | 6.69 | 14.8 | 7.65 | 22.1 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 4.84 | 4.07 | 13.2 | 6.47 | 22 |
Provision for Income Taxes | |||||
Net Income After Taxes | 1.95 | 2.61 | 13.1 | 5.62 | 15.9 |
Net Income Before Extraordinary Items | |||||
Net Income | 1.95 | 2.61 | 13.1 | 5.62 | 15.9 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 1.95 | 2.61 | 13.1 | 5.62 | 15.9 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.098 | 0.166 | 0.734 | 0.313 | 0.791 |
Dividends per Share |